Adobe Clinical Research, LLC — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2023	Research	$17,962	2
2021	Research	$27,769	3
2020	Research	$11,458	3
2019	Research	$800	1

Breakdown

Who paid Research payments · program years 2019–2023

Celgene Corporation $29,674 4 payments
Merck Sharp & Dohme Corporation $27,515 4 payments
Vanda Pharmaceuticals Inc. $800 1 payment

Studies the money was for Research payments · program years 2019–2023

A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals with Pre-cirrhotic Nonalcoholic Steatohepatitis $23,640 2 payments
PhIII RPC1063 Open Label Extension Moderate to Severe in UC (RPC01-3102) - A Phase 3, Multicenter, Open-Label Extension Trial of Oral RPC1063 as Therapy for Moderate to Severe Ulcerative Colitis $15,232 1 payment
(RPC01-3101) PhIII RPC1063 Induction and Maintenance in Moderate to Severe UC TRUENORTH (BMS Study Number: IM047-P22) $7,583 1 payment
A Phase 3, Multicenter, Randomized, Double-blind, $4,129 1 payment
A Phase 2b Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-3655 in Individuals with Pre-cirrhotic Nonalcoholic Steatohepatitis $3,875 2 payments
(RPC01-3101) PhIII RPC1063 Induction and Maintenance in Moderate to Severe UC TRUENORTH $2,730 1 payment
Study to Assess the Efficacy of VLY-686 in Relieving Symptoms of Gastroparesis $800 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.